Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage
2015 Standout
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
2016 Standout
Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report
2012 Standout
Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban
2013
Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial
2017
“Rescue” regimens after Helicobacter pylori treatment failure
2008
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding: A Systematic Review and Meta-analysis
2013
Contribution of platelets to tumour metastasis
2011 Standout
Prevention of VTE in Orthopedic Surgery Patients
2012 Standout
Therapy for Cancer-Related Thromboembolism
2014
Endocan: A novel inflammatory indicator in cardiovascular disease?
2015 Standout
Perioperative Management of Antithrombotic Therapy
2012 Standout
Glioblastoma and Other Malignant Gliomas
2013 Standout
New Antithrombotic Drugs
2012
Antithrombotic Therapy for VTE Disease
2016 Standout
Thromboembolic disease in patients with high-grade glioma
2012
Third-Line Rescue Therapy with Bismuth-Containing Quadruple Regimen After Failure of Two Treatments (with Clarithromycin and Levofloxacin) for H. pylori Infection
2013
Conflict of Interest in the Assessment of Thromboprophylaxis After Total Joint Arthroplasty
2012
Prevention of Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty
2005
Acute management of bleeding in patients on novel oral anticoagulants
2012
The effectiveness of rifabutin triple therapy for patients with difficult‐to‐eradicate Helicobacter pylori in clinical practice
2007
Prevention of VTE in Nonsurgical Patients
2012 Standout
Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti‐FXa assays
2014 StandoutNobel
Antithrombotic Therapy for VTE Disease
2012 Standout
Bleeding and antidotes in new oral anticoagulants
2013
The safety and efficacy of apixaban: where do we stand in 2013?
2013
Executive Summary
2012 Standout
Prevention of VTE in Nonorthopedic Surgical Patients
2012 Standout
Prevention of Venous Thromboembolism
2004 Standout
New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients
2014
Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation
2011
The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition
2016 Standout
A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects
2012
Efficacy and safety of oral anticoagulants in atrial fibrillation patients with cancer—a network meta-analysis
2019
Thrombosis and cancer
2012
Prevention of Venous Thromboembolism
2008 Standout
New anticoagulants: how to deal with treatment failure and bleeding complications
2011
Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy
2009 Standout
Cancer-associated venous thromboembolism: Burden, mechanisms, and management
2016
Review article: rifabutin in the treatment of refractoryHelicobacter pyloriinfection
2011
Novel oral anticoagulants: clinical pharmacology, indications and practical considerations
2013
Reversal of New, Factor-specific Oral Anticoagulants by rFVIIa, Prothrombin Complex Concentrate and Activated Prothrombin Complex Concentrate: A Review of Animal and Human Studies
2014
More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate
2015 StandoutNobel
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection
2017
Second Asia–Pacific Consensus Guidelines for Helicobacter pylori infection
2009
Photodynamic therapy for localized infections—State of the art
2009 Standout
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
2012
Cancer-associated thrombosis: investigating the role of new oral anticoagulants
2015
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
2021 Standout
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Management of glioblastoma: State of the art and future directions
2020 Standout
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
2017 Standout
[Treatment of cancer and thrombosis: practical approach].
2013
Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults.
2016
Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States
2017 Standout
International consensus statement on the peri‐operative management of anaemia and iron deficiency
2016 Standout
Emerging Therapies for the Treatment of Helicobacter pylori Infections
2008
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
2013
Apixaban, an oral, direct factor X a inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
2012
Hematological findings and complications of COVID ‐19
2020 Standout
Industry sponsorship and research outcome
2017 Standout
Works of Luz M. Ramirez being referenced
Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection
2007
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
2010
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer
2012
OC-03 Randomized phase II trial of an oral factor Xa inhibitor in patients with metastatic cancer on chemotherapy
2010
A randomized phase II trial of a new anticoagulant, apixaban, in metastatic cancer
2009